This new wallpaper collaboration with Mitchell Black captures the Lowcountry style with coastal designs that avoid typical ...

Partnership includes training program for medical students, focused on how to analyze clinical trial diversity data ATLANTA, GA – MARCH 31, 2025 – Morehouse School of Medicine (MSM) and the Catalyzing ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

Dark spots on the skin are usually not a cause for concern, but some people may choose to get rid of them for cosmetic reasons through laser treatment, microdermabrasion, and other methods. Dark ...

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...